Fosun Pharma Subsidiary Gains Green Light for DM1001 Drug Trial in Parkinson's Treatment

Stock News07-24

Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (SHA: 600196) has announced that its controlled subsidiary, Fosun Universal (Jiangsu) Pharmaceutical Group Co., Ltd., has received approval from China's National Medical Products Administration to conduct a clinical trial for DM1001 preparation.

The approval is specifically for the use of DM1001 preparation in treating the signs and symptoms of adult idiopathic Parkinson's disease. The subsidiary plans to initiate a Phase I clinical trial within China once conditions are suitable.

DM1001 preparation is classified as a chemical drug. According to the latest data from IQVIA CHPA, the sales of the same compound drug in China for 2025 were approximately 375 million yuan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149585123?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 16:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149585123","market":"us","top_or_hot":-1,"title":"Fosun Pharma Subsidiary Gains Green Light for DM1001 Drug Trial in Parkinson's Treatment","media":"Stock News","content":"<p><b>Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (SHA: 600196)</b> has announced that its controlled subsidiary, Fosun Universal (Jiangsu) Pharmaceutical Group Co., Ltd., has received approval from China's National Medical Products Administration to conduct a clinical trial for DM1001 preparation.<br><br>The approval is specifically for the use of DM1001 preparation in treating the signs and symptoms of adult idiopathic Parkinson's disease. The subsidiary plans to initiate a Phase I clinical trial within China once conditions are suitable.<br><br>DM1001 preparation is classified as a chemical drug. According to the latest data from IQVIA CHPA, the sales of the same compound drug in China for 2025 were approximately 375 million yuan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Subsidiary Gains Green Light for DM1001 Drug Trial in Parkinson's Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Subsidiary Gains Green Light for DM1001 Drug Trial in Parkinson's Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-24 16:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (SHA: 600196)</b> has announced that its controlled subsidiary, Fosun Universal (Jiangsu) Pharmaceutical Group Co., Ltd., has received approval from China's National Medical Products Administration to conduct a clinical trial for DM1001 preparation.<br><br>The approval is specifically for the use of DM1001 preparation in treating the signs and symptoms of adult idiopathic Parkinson's disease. The subsidiary plans to initiate a Phase I clinical trial within China once conditions are suitable.<br><br>DM1001 preparation is classified as a chemical drug. According to the latest data from IQVIA CHPA, the sales of the same compound drug in China for 2025 were approximately 375 million yuan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"","article_id":"1149585123","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149585123","pubTimestamp":1784883151,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (SHA: 600196) has announced that its controlled subsidiary, Fosun Universal (Jiangsu) Pharmaceutical Group Co., Ltd., has received approval from China's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK1593":"医美概念股","BK0175":"白马股","BK0060":"抗癌","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK1515":"抗疫概念","BK0196":"行业龙头","02196":"复星医药","BMED":"iShares Health Innovation Active ETF","BK0239":"医药制造","BK1191":"制药","BK0096":"民营医院","MDTX":"Corgi MediaTek 2x Daily ETF","PSYK":"PSYK ETF","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","BK0187":"一线龙头","BK0028":"国家队","IBBQ":"Invesco Nasdaq Biotechnology ETF"},"translate_title":"复星医药子公司获得治疗帕金森病的DM1001药物试验许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"MDTX":1,"PSYK":1,"IBBQ":1,"IBBJ":1,"02196":1,"BMED":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (SHA: 600196) has announced that its controlled subsidiary, Fosun Universal (Jiangsu) Pharmaceutical Group Co., Ltd., has received approval from China's National Medical Products Administration to conduct a clinical trial for DM1001 preparation.The approval is specifically for the use of DM1001 preparation in treating the signs and symptoms of adult idiopathic Parkinson's disease. The subsidiary plans to initiate a Phase I clinical trial within China once conditions are suitable.DM1001 preparation is classified as a chemical drug. According to the latest data from IQVIA CHPA, the sales of the same compound drug in China for 2025 were approximately 375 million yuan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149585123","isCrawlerRequest":true}